Latest Commercialisation News

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

Tlou Energy has commissioned its Kala Data Centre in Botswana, marking the first commercial revenue from its Coal Bed Methane gas resources and validating its integrated gas-to-power strategy.

Beamtree Holdings Limited reported a 2% rise in total revenue and a reduced net loss in the first half of FY26, driven by a 10% increase in recurring revenue. The company is advancing AI-powered healthcare products and has initiated a strategic review to unlock shareholder value.

PLS Group has acquired Calix’s stake in their joint lithium processing venture, gaining full ownership and operational control while securing a royalty-free licence for Calix’s calciner technology.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

Euro Manganese Inc. reported progress on its Chvaletice and Bécancour manganese projects, securing funding amendments and advancing permitting despite ongoing financial pressures. The company is positioned to benefit from growing demand for high-purity manganese in lithium-ion batteries amid evolving market dynamics.

Lincoln Minerals is sharpening its focus on copper exploration with a renewed push at its Minbrie Project and new collaborations targeting base metals and graphite markets.